Clinical Trials Logo
  1. Home
  2. Metabolism, Inborn Errors
  3. NCT03810690

Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia

Metabolism, Inborn Errors Clinical Trial

Official title:
A Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

Clinical Trial Summary

This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3704 in patients with methylmalonic acidemia/aciduria (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency between 1 to 18 years of age with elevated plasma methylmalonic acid. The study is designed to characterize baseline biomarker levels followed by assessment of safety, pharmacokinetics, and pharmacodynamics of different doses of mRNA-3704 in patients affected by MMA as part of the Dose Escalation phase. During the Dose Escalation phase, three dose levels of mRNA-3704 are planned to be investigated in this study among patients with MMA due to MUT deficiency: low dose, mid dose, and high dose. An additional cohort to evaluate a fourth dose level may be considered jointly by the independent SMC and the Sponsor. Upon establishment of a dose with acceptable safety and pharmacodynamic activity, additional patients will be enrolled in a Dose Expansion phase to allow for further characterization of the safety and pharmacodynamics of mRNA-3704. Patients in both phases of study will participate in a pre-dosing observational period, followed by a treatment period, and then a follow-up period after withdrawal of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03810690
Study type Interventional
Source ModernaTX, Inc.
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date May 28, 2019
Completion date August 18, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00010361 - Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders N/A
Terminated NCT01963650 - Natural History Study of Children With Metachromatic Leukodystrophy
Not yet recruiting NCT06337864 - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Recruiting NCT04999566 - Cardiac Manifestation and Inherited Metabolic Diseases
Completed NCT02826694 - North Carolina Newborn Exome Sequencing for Universal Screening N/A
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Active, not recruiting NCT02635269 - Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy N/A
Completed NCT00006061 - Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency N/A
Recruiting NCT04645498 - COVID-19 and Hereditary Metabolic Diseases
Completed NCT00099996 - Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia Phase 3
Completed NCT00006057 - Diagnostic and Screening Study of Genetic Disorders N/A
Withdrawn NCT02298712 - Biomarker for Hurler Disease (BioHurler)
Completed NCT00694109 - An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Phase 3
Completed NCT05123768 - Genetic Etiology in Patients With Cerebral Palsy